[Ethical aspects of clinical trials in rare diseases]

Area of Science:

• Medical Ethics
• Clinical Trial Regulation
• Rare Disease Research

Background:

• Approximately four million individuals in Germany are affected by rare diseases.
• Therapeutic research for rare diseases has gained significant attention over the past two decades.
• Drug research is subject to extensive regulations, with no exceptions for rare disease clinical trials.

Purpose of the Study:

• To examine the ethical assessment of clinical trials for rare diseases within the existing regulatory framework.
• To highlight the importance of biometric quality in ensuring ethical research conduct.
• To address specific challenges in sample size estimation and the role of pilot studies.

Main Methods:

• Analysis of German drug laws, regulations, and ethical conventions governing clinical trials.
• Review of ethical assessment criteria for clinical trial applications, irrespective of disease frequency.
• Focus on biometric aspects: study design, sample size estimation, and statistical analysis.

Main Results:

• Ethical standards for rare disease trials are equivalent to those for common diseases, rooted in constitutional rights and codified in law.
• Methodological deficiencies in research are considered inherently unethical.
• Pilot studies should be minimized, and sample size calculations must avoid overly optimistic effect sizes and maintain a 5% two-sided error probability.

Conclusions:

• The ethical evaluation of rare disease clinical trials aligns with general clinical research standards.
• Robust study design, accurate sample size determination, and sound statistical analysis are paramount for ethical research.
• Avoiding pilot studies and employing conservative statistical assumptions are recommended for rare disease research.